INS and type 2 diabetes mellitus: A post hoc analysis of pooled data from six trials of exenatide bid in patients with T2DM compared with placebo and insulin (n = 2171) demonstrated a significant reduction in SBP relative to placebo and insulin comparators with a weak correlation to weight loss (r= 0.09, P= 0.002).